New healthcare accelerator open for applications at Stevenage Bioscience Catalyst

Pre-clinical therapeutics startups are being urged to sign up for the 2025 accelerator programme being run by Stevenage Bioscience Catalyst (SBC). Catalyser 2025 is designed to help young companies in the sector attract investors/partners and maximise their overall chances of success.

Dr Sally Ann Forsyth, CEO at Stevenage Bioscience Catalyst, with the Aga Nanotech team at last year’s event. Courtesy – SBC.

The programme is supported by Hertfordshire Futures and Pharmidex and there is a relatively short window to enrol. Applications must be received by April 25 for a programme that runs from May 8 to June 26.

Catalyser 2025 is open to pre-clinical therapeutics startups based in the UK or planning to establish a presence here. Their innovations must obviously be for the benefit of human health and the companies should be en route to building a first proof of concept. They must also have integrated digital and data technologies (ie ML/AI) in their R & D workflow or are planning to integrate them.

SBC says there are several opportunities for participants, such as:-

• Participants get the opportunity to refine their commercialisation strategy with Triple Chasm framework – six highly-interactive sessions focusing on nine strategy topics from market definition and proposition framing to IP strategy, human capital and strategic positioning.

• The cohort can access a complimentary package of CRO services from award-winning Pharmidex: Selected companies will receive tailored services to support their preclinical development.

• Those involved will be part of a cohort of eight pre-clinical therapeutics startups, to share challenges with and discuss best strategies.

• There is the opportunity to access the world: connecting with SBC’s community of 40 therapeutics businesses to strengthen the network for startups.

Key sessions in the programme will be held on May 8, 15, 22, 29 and June 5 & 26.

Rory Ryan, CEO and Co Founder of PentaBind, which participated in the last programme, commented: “We highly recommend joining Stevenage Bioscience Catalyst. The team have been incredibly supportive and have had a massive impact on our refining company's strategy.”

Chris Ullman, CEO, Stratosvir, added: “Unlike other accelerators, a data-driven programme that supports start-ups to grow into competitive companies. Very rewarding, and not just geared towards a pitch day event.”

Newsdesk

news@businessweekly.co.uk